Bavarian Nordic jumps on Q2 beat, outlook hike amid soaring vaccine sales

Bavarian Nordic A/S

21/08/2026 08:10

** Shares in Bavarian Nordic BAVA.CO rise 7% after the Danish vaccine maker posted Q2 revenue 35% above expectations and nudged up its FY outlook
** It posts quarterly sales at 2.03 billion Danish crowns ($318 million), while Jefferies says consensus expected 1.51 billion crowns
** Its revenue in the travel health business rises 45% in the quarter; the demand for its rabies vaccines remains exceptionally strong across key markets
** Jefferies says Q2 revenue and profits beat is solid, driven by mpox timing and travel outperformance
** The company also launches a new share buyback of 750 million crowns, which Jefferies says should be well received
** Bavarian Nordic shares set for best day since July 2025
($1 = 6.3921 Danish crowns)

(Reporting by)